secwatch.observer — SEC 8-K summary
======================================

Issuer:     HALOZYME THERAPEUTICS, INC. (HALO)
CIK:        0001159036
Form:       8-K/A
Filed at:   2022-08-09T23:59:59+00:00
Accession:  0001159036-22-000051
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Halozyme completes Antares acquisition for $5.60/sh; total consideration ~$1.0457B
--------------------------------------------------------------------------------

- Aggregate purchase consideration $1,045.7M; each Antares share converted into $5.60 cash.
- Pro forma combined 2021 revenue $627.3M, net income $286.2M; basic EPS $2.04.
- Pro forma Q1 2022 revenue $158.8M, net income $36.2M; basic EPS $0.26.
- Financing includes $250M term loan and $350M revolving credit facility from BofA.
- Nonrecurring acquisition-related costs of $40.5M expensed in pro forma statements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000051/0001159036-22-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1159036/000115903622000051/halo-20220524.htm
  HTML page:      https://secwatch.observer/filing/0001159036-22-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer